123I-FP-CIT brain SPECT (DaTSCAN) imaging in the diagnosis of patients with movement disorders – First results

SPECT scintigraphy of the brain using 123I-FP-CIT (DaTSCAN) in patients with extrapyramidal diseases – First results

Ljiljana Jauković*, Tihomir V. Ilić†, Marija Dopudja*, Boris Ajdinović‡

Military Medical Academy, *Institute of Nuclear Medicine, †Clinic of Neurology, Belgrade, Serbia

Abstract

Background/Aim. 123I-FP-CIT brain single-photon emission computed tomography (SPECT), DaTSCAN imaging, offers a possibility to study structural and biochemical integrity of presynaptic dopaminergic neurotransmitter system. The aim of this study was to evaluate the usefulness of 123I-FP-CIT brain SPECT scintigraphy in patients with extrapyramidal disorders. Methods. Fifteen patients (8 males and 7 females), aged 26–81 years, presenting with extrapyramidal symptoms entered the study. Out of them, 7 patients were diagnosed with definite clinical form of idiopathic Parkinson’s disease (PD) or clinical probable for PD clinical stage 2–4 using the Hoehn&Yahr scale (H&Y); 6 patients were with atypical parkinsonism (AP), 1 patient with essential, and 1 with psychogenic tremor. SPECT was performed 180 min after injection of 185 MBq 123I-FP-CIT using a dual head Gamma camera. Sixty four one minutes' frames were acquired using a noncircular rotation mode into a 128 × 128 image matrix. Transverse slices were reconstructed using a 0.6 order Butterworth filter. Visual interpretation was based on striatal uptake, left to right asymmetry and structures most affected. The ratio of binding for the entire striatum, caudate and putamen to non-specific binding in occipital cortex was calculated. SPECT findings were categorized as normal and abnormal (incipient, moderate and severe presynaptic deficit). Results. 123I-FP-CIT uptake was reduced in the striatum of 6/7 patients with PD and 5/6 patients with AP. Two patients with PD and AP showed a negative finding. The remaining 2 negative results were obtained in the patients diagnosed with essential tremor and psychogenic tremor. The mean striato-occipital ratio (SDR) of the most affected side was lower in the patients with PD. Conclusion. Our first results confirm the usefulness of 123I-FP-CIT brain SPECT in differential diagnosis of extrapyramidal diseases.

Key words: parkinsonian disorders; Parkinson disease; diagnosis, differential; tomography, emission-computed, single photon; radionuclide imaging.

Apstrakt

pouszdanim dijagnozom ili sumnjom na PD, kao i kod pet od šest bolesnika sa AP. Dva negativna nalaza dobijena su kod dve bolesnice sa PD i AP. Preostala dva negativna nalaza dobijena su kod dva bolesnika sa esencijalnim, odnosno psihogenim tremorom. Srednja vrednost strijato-okcipitalnog indeksa vezivanja na zahvaćenoj strani mozga bila je niža kod bolesnika sa PD. Zaključak. Naši prvi rezultati potvrđuju doprinos ¹²³I-FP-CIT SPECT scintigrafijskoj mozga u diferencijalnoj dijagnostici bolesnika sa ekstrapiramidnim poremećajima.

**Ključne reči:** parkinsonov sindrom; parkinsonova bolest; dijagnoza, diferencijalna; tomografija, komjuterizovana, emisiona, jednofotonska; scintigrafija.

---

**Introduction**

The term Parkinson’s disease refers to a group of neurodegenerative conditions considered to primarily come from abnormalities of basal ganglia function. PD is one of the most common neurodegenerative diseases affecting about 329 per 100,000 people (age-adjusted prevalence rate). Although the etiology of PD is not completely understood, the condition probably results from a combination of polygenic inheritance, environmental exposures, and gene–environment interactions. Data has implicated mitochondrial dysfunction, oxidative damage, aberrant protein aggregation, and deficits in ubiquitin-mediated protein degradation as playing key roles in the etiopathogenesis of PD. In PD degeneration of dopaminergic neurons and their projection to the striatum is a slowly evolving process that may take decades to develop. In most cases the diagnosis of PD is straightforward when cardinal clinical signs and symptoms as bradykinesia, rigidity, and resting tremor are present. However, these main features of PD are shared, at least in part by essential tremor, multisystem atrophy, progressive supranuclear palsy, vascular parkinsonism, dementia with Lewy bodies, corticobasal degeneration, Alzheimer’s disease, and drug-induced parkinsonism. Besides, delineating PD from the above-mentioned parkinsonian disorders distinguishing PD from normality can also be difficult, especially in early stage of the disease.

A reliable test to diagnose PD is important for at least two reasons. Prognosis and management of PD and other parkinsonian disorders differ considerably, and an objective disease marker would facilitate the development of neuroprotective therapies. Several procedures have been proposed to diagnose PD: functional imaging with positron emission tomography (PET) or single photon emission computed tomography (SPECT), transcranial sonography, olfactory and neuropsychological tests, biomarkers and DNA tests.

Imaging of the dopaminergic system with SPECT is used since radiopharmaceuticals for imaging the presynaptic dopaminergic transporter, as well as the dopamine D2 receptors became commercially available.

Dopamine transporters are localized on dopaminergic nerve endings and are lost in the process of degeneration in PD. They can be used as markers for the integrity or for the degree of loss of dopaminergic nerve endings. The cocaine derivative ¹²³I-labeled N-(3-fluoropropyl)-28-carbethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) (DaTSCAN, GE Healthcare) binds with high affinity to dopamine reuptake sites in the striatum and can be used to visualize dopaminergic nerve terminals in vivo in the human brain. The nuclear medicine method – brain SPECT with ¹²³I-FP-CIT is a valuable tool for discriminating neurodegenerative parkinsonian syndromes with an associated presynaptic dopaminergic deficit from diseases without presynaptic neurodegeneration. ¹²³I-FP-CIT is a sensitive marker of dopaminergic degeneration, and the degree of striatal binding reduction in PD correlates with disease severity. Dopamine transporter imaging offers the prospect of a quick, objective method to confirm or exclude presynaptic parkinsonism (PD) in inconclusive cases.

The aim of the study was to evaluate our first results with ¹²³I-FP-CIT SPECT in patients with extrapyramidal diseases.

**Methods**

Since January 2009, 15 patients (age range 26–81, median 67 years) with clinical findings suggestive of extrapyramidal disorders have been referred to our institution for ¹²³I-FP-CIT brain SPECT. All parkinsonian patients fulfilled clinical diagnostic criteria for PD. The disease staging (modified Hoehn &Yahr score) was given at the time of SPECT examination all but one patient with PD and atypical parkinsonism (AP) (range 1.00–4.00, mean 2.70 ± 1.07 standard deviation).

Thyroid uptake was blocked before the scan by administration of 400 mg of perchlorate at least 30 min prior to the injection. All subjects received 150–185 MBq (4–5 mCi) of ¹²³I-FP-CIT in slow intravenous injection. During the acquisition, the patient’s head was fixed in with elastic band to minimize motion artifacts.

Acquisition started between 3 and 4 hours after intravenous injection of commercially available radiopharmaceutical ¹²³I-FP CIT (DaTSCAN, GE Healthcare). Data were acquired with a double-head camera (Vertex, Adac) using low-energy–general-purpose collimators, in 64 × 64 matrix size. Sixty four projections were acquired at 60 s per view with the camera heads following a non-circular orbit, resulting in a total scan time of 32 min. Total brain count of more than 1.5 million was achieved in all examinations. SPECT data were reconstructed by back projection filtered with a Butterworth filter (0.6 cut of value, order 8).

SPECT images were interpreted visually and semiquantitatively using region of interest techniques to assess specific ¹²³I-FP-CIT binding in striatum and striatal subregions.

The findings were classified as normal if symmetric intense tracer uptake in striatum and striatal subregions presented. Abnormal findings were categorized as incipient, moderate and severe presinaptic deficit. Incipient presinaptic deficit was defined as asymmetrical one-sided slightly re-

---

duced putamen uptake. Moderate presinaptic deficit was defined as reduction in specific/non-specific tracer binding and poor visualization of putamen in both sides, and, finally, severe presinaptic deficit as significant reduction of specific binding resulting in visualization of background activity through the brain hemispheres.

For analysis of striatal 123I-FP-CIT binding, 3 transaxial slices representing the most intense striatal binding were summed. Irregular regions of interest were constructed manually in areas corresponding to the right and left striatum, caudate, and putamen. Irregular regions of interest were also drawn in area corresponding to the occipital cortex (Figure 1).

The mean specific basal ganglia binding was calculated from the mean counts per pixel in the whole striatum, caudate nucleus, and putamen (specific binding), dividing the results by the mean counts per pixel in the occipital cortex (non-specific binding). The ratios expressed as mean ± standard deviation, were compared between the patients.

**Results**

Subject demographic data are given in Table 1. Four patients had normal striatal 123I-FP-CIT binding (Figure 2) with no significant differences in striatal or subregional binding ratios. Eleven patients had abnormal 123I-FP-CIT SPECT findings – assigned as incipient, moderate and severe presinaptic deficit was found in 2, 5 and 4 patients, respectively (Figures 3 and 4). Subanalyses showed diminished

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PD</th>
<th>AP</th>
<th>ET/PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients number</td>
<td>7</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Age (year) (X ± SD)</td>
<td>66.7 ± 8.8</td>
<td>59.8 ± 20.3</td>
<td>65.0 ± 21.2</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>3/4</td>
<td>4/2</td>
<td>1/1</td>
</tr>
<tr>
<td>Modified H&amp;Y score</td>
<td>2.42 ± 0.93</td>
<td>3.10 ± 1.24*</td>
<td>—</td>
</tr>
</tbody>
</table>

*1 patient missing; AP – atypical parkinsonism, ET – essential tremor, PT – psychogenic tremor, H&Y score – Hoehn&Yahr score

![Fig. 1 – Irregular regions of interest were constructed manually in areas corresponding to the right and left striatum, caudatum, putamen, and occipital cortex](image1)

![Fig. 2 – Normal 123I-FP-CIT SPECT in patient with essential tremor](image2)

![Fig. 3 – 123I-FP-CIT SPECT interpreted as moderate presinaptic dopaminergic deficit in patient with Parkinson’s disease (clinical stage 2.0 H&Y)](image3)
binding in the caudate (2.15 ± 0.56 and 2.16 ± 0.56 for the right and left caudate, respectively), diminished binding in the putamen (1.82 ± 0.32 and 1.86 ± 0.47 for the right and left putamen, respectively).

$^{123}$I-FP-CIT binding ratios in the whole striatum, the caudate, and the putamen are presented in Table 2.

**Table 2** Specific $^{123}$I-FP-CIT uptake ratio observed in striatum, caudatum, and putamen of patients with Parkinson’s disease (PD)

<table>
<thead>
<tr>
<th>Patient N°</th>
<th>Clinical diagnosis</th>
<th>SPECT visually estimated*</th>
<th>Striatal region</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Striatum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>R</td>
</tr>
<tr>
<td>1</td>
<td>PD</td>
<td>3</td>
<td>1.09</td>
</tr>
<tr>
<td>2</td>
<td>PD</td>
<td>1</td>
<td>1.77</td>
</tr>
<tr>
<td>3</td>
<td>ET</td>
<td>1</td>
<td>3.72</td>
</tr>
<tr>
<td>4</td>
<td>AP</td>
<td>5</td>
<td>1.65</td>
</tr>
<tr>
<td>5</td>
<td>AP</td>
<td>3</td>
<td>1.87</td>
</tr>
<tr>
<td>6</td>
<td>PD</td>
<td>2</td>
<td>1.89</td>
</tr>
<tr>
<td>7</td>
<td>PD</td>
<td>3</td>
<td>1.97</td>
</tr>
<tr>
<td>8</td>
<td>AP</td>
<td>3</td>
<td>2.5</td>
</tr>
<tr>
<td>9</td>
<td>PD</td>
<td>5</td>
<td>1.97</td>
</tr>
<tr>
<td>10</td>
<td>PT</td>
<td>1</td>
<td>2.37</td>
</tr>
<tr>
<td>11</td>
<td>PD</td>
<td>5</td>
<td>1.38</td>
</tr>
<tr>
<td>12</td>
<td>PD</td>
<td>3</td>
<td>2.12</td>
</tr>
<tr>
<td>13</td>
<td>AP</td>
<td>1</td>
<td>2.62</td>
</tr>
<tr>
<td>14</td>
<td>AP</td>
<td>2</td>
<td>2.27</td>
</tr>
<tr>
<td>15</td>
<td>AP</td>
<td>5</td>
<td>1.72</td>
</tr>
</tbody>
</table>

$\bar{x}$ ± SD 2.06 ± 0.62 2.03 ± 0.58 2.38 ± 0.76 2.45 ± 0.87 2.10 ± 0.71 2.01 ± 0.61

AP – atypical parkinsonism, ET – essential tremor, PT – psychogenic tremor, R – right, L – left,

*1 – normal DaTSCAN, 2 – incipient presynaptic deficit, 3 – moderate presynaptic deficit, 5 – severe presynaptic deficit

**Discussion**

There is no confirmatory test for PD except the histopathological one. Although idiopathic PD represents the most prevalent form of Parkinson’s syndrome, at early stages of disease it could be difficult to differentiate idiopathic PD from other forms of parkinsonism solely on clinical grounds, taking in considerations that share, at least partially, similar symptoms such as tremor, bradykinesia, rigidity, gait disturbance, speech or swallowing difficulties and autonomic dysfunction.

Out of 15 patients enrolled in our study, seven were already diagnosed patients with clinical definite form of idiopathic PD either clinical probable for PD. All but one patient had a pathological $^{123}$I-FP-CIT SPECT finding graded as moderate to severe presynaptic dopaminergic deficit. Normal $^{123}$I-FP-CIT SPECT findings was obtained in a 72-year old woman diagnosed with PD in early stage (H&Y = 2). Rather than the false negative result, the plausible explanation may be that the patient initially diagnosed as having PD actually have another disorder; moreover, taking into account that it occurs in 10%–25% of PD cases when reviewed pathologically. In addition, approximately 10% of patients diagnosed clinically with early PD have normal dopaminergic functional imaging (Scans Without Evidence of Dopaminergic Deficit [SWEDDs]) in tremulous patients in comparison with tremor-dominant PD patients showing that underlying pathophysio-
ology of SWEDDs differs from PD but has similarities with primary dystonia. Distinguishing these patients from PD is important, cause the correct diagnosis will help avoid inappropriate PD drug treatments. Study comparing DaT-SPECT results in autopsy findings in 25 patients with Parkinsonian disorders suggests that DaT-SPECT can reliably document dopaminergic degeneration in Lewy body disorders.

The mean striatal FP-CIT binding was decreased in our patients already diagnosed as having PD (1.79 ± 0.36, 1.81 ± 0.35 for the right and left striatum, respectively), concordantly with literature data. Striatal 123I-FP-CIT binding is reduced in PD in proportion to disease severity. Studies with 6-18F-fluoro-L-dopa PET suggest that the disease process in PD first affects the posterior putamen, followed by the anterior putamen and the caudate nucleus. Our results showed that the putamen 123I-FP-CIT binding was markedly reduced in subgroup of PD patients (1.73 ± 0.40, 1.76 ± 0.39 for the right and left putamen, respectively) vs the mean putamen binding (2.10 ± 0.71, 2.01 ± 0.61 for the right and left putamen, respectively) (Table 2).

Clinical rating scales, H&Y and the Unified Parkinson’s Disease Rating Scale (UPDRS) scores, have a high sensitivity and specificity for the clinical diagnosis of PD. These rating scales, however, are more difficult to apply in patients with atypical parkinsonism. The clinical diagnosis is most difficult early in the disease when the signs and symptoms are quite subtle. Moreover, symptoms in PD become apparent only after a critical level of cell loss — the “symptom threshold” — requiring a loss of approximately 80% of dopamine innervation.

We found interesting a case of 50-year-old woman with atypical parkinsonian syndrome and a 123I-FP-CIT SPECT finding suggestive for PD performed in another institution 9 months ago. For the reason she clinically was not likely to be diagnosed with PD, we obtained a control scan. The typical abnormal finding consisting for the severe presinaptic deficit in PD was shown. Our finding contributed to clinical characterization of patient, which is of importance in therapy selection and prognosis.

Several studies on patients with known PD in early stage showed the ability to differentiate between PD and normally with 100% specificity. In distinguishing Alzheimer disease from Dementia Lewy body, in vivo findings of presynaptic dopaminergic imaging correlated well with neuropathological findings at autopsy, suggesting a remarkable sensitivity of 77%–88% and a specificity of 87.9%–100.0%.

According to the results of a meta-analysis of the literature data on diagnostic accuracy of SPECT in parkinsonian syndromes, SPECT with presynaptic radiotracer are highly accurate in differentiation between patients with PD and essential tremor. We had only two patients with clinical diagnosis suggestive to essential or psychogenic tremor and we obtained normal results in both of them. Normal SPECT FP-CIT finding enabled clinicians to exclude a neurodegenerative parkinsonian syndrome. The use of 123I-FP-CIT SPECT can prove or exclude high sensitivity nigrostriatal dysfunction in cases of monosymptomatic tremor (dystonic tremor, essential tremor, Parkinson tremor) and facilitates early and accurate diagnosis. Furthermore, a normal 123I-FP-CIT SPECT is helpful in supporting a diagnosis of drug-induced, psychogenic and vascular parkinsonism by excluding underlying true nigrostriatal dysfunction.

Recent study of Antonioni et al. reported that 123I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate essential tremor from PD, increasing time on potentially beneficial therapy at a lower cost to healthcare system.

In addition, the study comparing the scanning techniques 123I-FP-CIT and F-DOPA (positron emission tomography technique) reported the sensitivity of 91% for both and specificity of 100% and 90% for 123I-FP-CIT and F-DOPA, respectively, in the diagnosis of presynaptic dopaminergic deficits in early phases of PD.

A limitation of our study is that we did not include the healthy volunteer control group because of the absence of validated control population for 123I-FP-CIT. In addition, manually constructed regions of interest may be the source of errors, as well. Using voxel-based analysis with anatomic standardization or validated an automated technique combining perfusion and 123I-FP-CIT SPECT may contribute in the differential diagnosis of parkinsonism under clinical circumstances.

Conclusion

Imaging presynaptic dopamine transporter as an important diagnostic tool for patients with parkinsonian syndromes has become a routine clinical procedure in nuclear medicine departments in Europe. The technique is relatively accurate to differentiate patients with PD in an early phase from healthy one, patients with PD from those with essential tremor, and PD from vascular parkinsonism.

Based on the first 15 123I-FP-CIT SPECT studies performed in our Institute, we showed that 123I-FP-CIT SPECT studies provide useful information used to confirm or exclude PD leading to change the diagnosis and patient management. 123I-FP-CIT SPECT can therefore be considered useful tool in the diagnosis of patients with atypical clinical presentation of PD.

References


